Understanding the pharmacology of sympathomimetic agents and the physiologic consequences of adrenergic receptor stimulation allows clinicians to prevent undesirable effects and achieve specific therapeutic goals.
Answers are grounded in this paper and cite their sources.
Receptor selectivity guides tailored vasopressor use in shock; leaves open head-to-head trials for optimal agent selection.
OBJECTIVE: To review the physiologic and pathophysiologic hyperadrenergic states and the pharmacologic use of sympathomimetic agents. DATA SOURCES: Pharmacologic and physiologic studies in experimental animals and humans. DATA EXTRACTION/SYNTHESIS: Plasma catecholamines are increased in a variety of clinical situations. Following major injury, catecholamines act to support vital organ perfusion and mobilize fuel substrates. However, with surgical trauma and during acute medical illnesses, such as myocardial infarction, catecholamine-induced physiologic changes can interact with underlying disease processes to result in clinically significant complications. Exogenous catecholamines are used to treat a variety of medical conditions, including anaphylaxis and various shock states. Available sympathomimetic agents differ in their availability to stimulate different subpopulations of adrenergic receptors. These differences permit the astute clinician to achieve specific physiologic end-points. Finally, plasma catecholamines are increased in patients with pheochromocytoma. This latter condition provides insights into the long-term effects of catecholamine excess. CONCLUSIONS: Based on knowledge of the pharmacology of sympathomimetic agents and the physiologic consequences of adrenergic receptor stimulation, it is possible to prevent undesirable catecholamine effects and to utilize these agents to achieve desired therapeutic goals.
No takes yet. Share an insight, caveat, or question.
Breslow et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: